当前位置: 首页 > 详情页

VEGF, a Key Factor for Blood-Brain Barrier Injury during Cerebral Ischemia

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China [3]Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China [4]Beijing Geriatr Med Res Ctr, Beijing, Peoples R China [5]Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China [6]Capital Med Univ, Beijing Inst Brain Disorders, Beijing, Peoples R China
出处:
ISSN:

关键词: BBB cerebral ischemia VEGF

摘要:
Blood brain barrier (BBB) injury is an important factor affecting the prognosis of ischemic stroke. Extensive research on BBB injury has revealed that blood vessels and neural networks are interdependent and interrelated during and after the development of the brain. An array of signaling molecules, known as angioneurins, can affect both blood vessels and neural networks simultaneously. Angioneurins not only regulate the angiogenesis and remodeling process of the vascular system, but also act as neurotrophic and neuroprotective factors, or serve as guide molecules for axons. Vascular endothelial growth factor (VEGF) is a type of angioneurin that is expressed in neurons, astrocytes, macrophages, and vascular endothelial cells in ischemic and hypoxic brain tissues after cerebral ischemia. VEGF can increase and induce the destruction of the endothelial barrier in the early stages of cerebral ischemia. Both the upregulation of endogenous VEGF levels and the use of exogenous VEGF are harmful in the acute stage of stroke. However, the harmful effects of VEGF on vascular integrity are transient. Several studies have shown that VEGF regulates angiogenesis, neurogenesis, neurite growth and brain edema after cerebral ischemia. Therefore, it is crucial to understand the dual role of VEGF in ischemic stroke. The following will focus on the damage caused by VEGF to the BBB in the context of cerebral ischemia, as well as therapeutic studies targeting VEGF.

基金:

基金编号: 82001390 82171301 82171303 2020-2-1032

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 2 区 老年医学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 老年医学
JCR分区:
出版当年[2019]版:
Q1 GERIATRICS & GERONTOLOGY
最新[2023]版:
Q1 GERIATRICS & GERONTOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Xuanwu Hosp, Inst Cerebrovasc Dis Res, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing, Peoples R China [3]Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China [4]Beijing Geriatr Med Res Ctr, Beijing, Peoples R China [5]Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China [6]Capital Med Univ, Beijing Inst Brain Disorders, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院